Dicerna Pharmaceuticals
NEWS
Dicerna Pharmaceuticals was acquired by Novo Nordisk in December 2021.
Under the terms of the deal, Roche will pay Dicerna $200 million upfront and up to another $1.47 billion for various development, regulatory and commercial milestones.
Dicerna Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced it has submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA).
Biotech and pharma companies strengthen their leadership teams and committees with new appointments.
Movers and Shakers is BioSpace’s weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
For the second time in less than one week, Dicerna Pharmaceutical has forged a licensing agreement for its GalXC RNAi technology platform. This time Dicerna and Eli Lilly have struck an agreement to use the platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.
Shares of Alexion Pharmaceuticals are up nearly 4 percent in premarket trading after the company announced it has teamed up with Dicerna Pharmaceuticals on the development of an RNAi therapeutic for the treatment of complement-mediated diseases.
Here’s a look at who shook things up in the world of pharma and biotech this week.
The past few days has had a flurry of activity in the industry with leadership changes. Let’s take a look at some of those!
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
IN THE PRESS